Patients who subsequently relapsed showed markedly higher levels of MAGE-A10 and CA125 expression (p = 0.09 and p = 0.08, respectively) in the primary tumor samples in comparison to patients who remained in remission (Figure 2). This evidence concerns the gene MAGEA10 and neoplasm.